Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

India is facing a silent epidemic of non-alcoholic fatty liver disease, especially affecting young people. Around 1 to 3 ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

A recommended 150 minutes per week at moderate intensity can help reduce liver inflammation and rid the organ of fat. Antioxidants and other compounds in coffee (even decaf) can help protect against ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic dysfunction–associated steatotic liver disease.

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...